United States Immigration and Customs Enforcement is leveraging Palantir’s generative artificial intelligence tools to sort and summarize immigration enforcement tips from its public submission form, ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
SIMI VALLEY, California.—The White House has greenlit a plan to design and build a frigate domestically as part of its proposed “Golden Fleet,” Navy Secretary John Phelan announced at the Reagan ...
Department of Analytical Chemistry, Faculty of Chemistry, K.N. Toosi University of Technology, P.O. Box 16315-1618, Postal Code 15418-49611 Tehran, Iran Nanomaterial, Separation and Trace Analysis ...
Peraton, formerly part of Harris Corp., will be responsible for steering the massive ATC modernization effort ...
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
(RTTNews) - Chart Industries, Inc. (GTLS), Wednesday announced an agreement to merge with Flowserve Corp. (FLS), creating a combined entity with an expected enterprise value of approximately $19 ...
Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results